LianBio (NASDAQ:LIAN) Shares Up 5%

LianBio (NASDAQ:LIAN) shares rose 5% during mid-day trading on Monday . The stock traded as high as $0.32 and last traded at $0.32. Approximately 201,363 shares changed hands during trading, a decline of 81% from the average daily volume of 1,037,083 shares. The stock had previously closed at $0.30.

LianBio Price Performance

The stock’s 50-day moving average is $0.32 and its 200-day moving average is $2.17. The stock has a market cap of $32.96 million, a price-to-earnings ratio of -0.38 and a beta of 0.23.

Institutional Trading of LianBio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Axxcess Wealth Management LLC purchased a new position in shares of LianBio in the 3rd quarter worth $25,000. Donald L. Hagan LLC raised its holdings in shares of LianBio by 37.3% in the 4th quarter. Donald L. Hagan LLC now owns 20,600 shares of the company’s stock worth $92,000 after purchasing an additional 5,600 shares during the period. Finally, Affinity Asset Advisors LLC raised its holdings in shares of LianBio by 462.2% in the 4th quarter. Affinity Asset Advisors LLC now owns 3,779,694 shares of the company’s stock worth $16,895,000 after purchasing an additional 3,107,337 shares during the period. Hedge funds and other institutional investors own 74.85% of the company’s stock.

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.